Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies

by Hilma J. van der Horst, Simone C. Oostindie, Saskia. A. G. M. Cillessen, Anne T. Gelderloos, Marije B. Overdijk, Inger. S. Nijhof, Sonja Zweegman, Martine E. D. Chamuleau, Esther C. W. Breij, Tuna Mutis
Published 2021-01-01

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment

by Hilma J. van der Horst, A. Vera de Jonge, Ida H. Hiemstra, Anne T. Gelderloos, Daniella R. A. I. Berry, Nathalie J. Hijmering, Hendrik F. van Essen, Daphne de Jong, Martine E. D. Chamuleau, Sonja Zweegman, Esther C. W. Breij, Margaretha G. M. Roemer, Tuna Mutis
Published 2021-02-01

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

by Patrick J. Engelberts, Ida H. Hiemstra, Bart de Jong, Danita H. Schuurhuis, Joyce Meesters, Irati Beltran Hernandez, Simone C. Oostindie, Joost Neijssen, Edward N. van den Brink, G. Jean Horbach, Sandra Verploegen, Aran F. Labrijn, Theodora Salcedo, Janine Schuurman, Paul W.H.I Parren, Esther C.W. Breij
Published 2020-02-01